These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24074025)

  • 1. Investigating the selectivity of metalloenzyme inhibitors.
    Day JA; Cohen SM
    J Med Chem; 2013 Oct; 56(20):7997-8007. PubMed ID: 24074025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metalloprotein-inhibitor binding: human carbonic anhydrase II as a model for probing metal-ligand interactions in a metalloprotein active site.
    Martin DP; Hann ZS; Cohen SM
    Inorg Chem; 2013 Nov; 52(21):12207-15. PubMed ID: 23706138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.
    Nuti E; Orlandini E; Nencetti S; Rossello A; Innocenti A; Scozzafava A; Supuran CT
    Bioorg Med Chem; 2007 Mar; 15(6):2298-311. PubMed ID: 17276072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the Selectivity of Metalloenzyme Inhibitors in the Presence of Competing Metalloproteins.
    Chen Y; Cohen SM
    ChemMedChem; 2015 Oct; 10(10):1733-8. PubMed ID: 26412596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isosteres of hydroxypyridinethione as drug-like pharmacophores for metalloenzyme inhibition.
    Adamek RN; Credille CV; Dick BL; Cohen SM
    J Biol Inorg Chem; 2018 Oct; 23(7):1129-1138. PubMed ID: 30003339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metalloprotein Inhibitors for the Treatment of Human Diseases.
    Yang Y; Hu XQ; Li QS; Zhang XX; Ruan BF; Xu J; Liao C
    Curr Top Med Chem; 2016; 16(4):384-96. PubMed ID: 26268345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.
    Musso L; Cincinelli R; Zuco V; Zunino F; Nurisso A; Cuendet M; Giannini G; Vesci L; Pisano C; Dallavalle S
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4457-60. PubMed ID: 26376355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
    Roth L; Gotsbacher MP; Codd R
    J Med Chem; 2020 Oct; 63(20):12116-12127. PubMed ID: 32940035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Metalloenzymes for Therapeutic Intervention.
    Chen AY; Adamek RN; Dick BL; Credille CV; Morrison CN; Cohen SM
    Chem Rev; 2019 Jan; 119(2):1323-1455. PubMed ID: 30192523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calorimetric studies of the interactions of metalloenzyme active site mimetics with zinc-binding inhibitors.
    Robinson SG; Burns PT; Miceli AM; Grice KA; Karver CE; Jin L
    Dalton Trans; 2016 Jul; 45(29):11817-29. PubMed ID: 27373714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.
    Scozzafava A; Supuran CT
    J Med Chem; 2000 Oct; 43(20):3677-87. PubMed ID: 11020282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
    Suzuki T; Kouketsu A; Matsuura A; Kohara A; Ninomiya S; Kohda K; Miyata N
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3313-7. PubMed ID: 15149697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual effects of caffeoyl-amino acidyl-hydroxamic acid as an antioxidant and depigmenting agent.
    Kwak SY; Lee S; Choi HR; Park KC; Lee YS
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5155-8. PubMed ID: 21840713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid-phase synthesis of N-formylhydroxylamines (reverse/retro-hydroxamates).
    Price S; Osbourn SE
    Org Lett; 2005 Aug; 7(17):3761-3. PubMed ID: 16092869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modifications around the hydroxamic acid chelating group of fosmidomycin, an inhibitor of the metalloenzyme 1-deoxyxylulose 5-phosphate reductoisomerase (DXR).
    Zinglé C; Kuntz L; Tritsch D; Grosdemange-Billiard C; Rohmer M
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6563-7. PubMed ID: 23025997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Metalloenzymes by Boron-Containing Metal-Binding Pharmacophores.
    Xiao YC; Yu JL; Dai QQ; Li G; Li GB
    J Med Chem; 2021 Dec; 64(24):17706-17727. PubMed ID: 34875836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metalloenzymes as Therapeutic Targets.
    Richichi B; Spyroulias GA; Winum JY; Žalubovskis R
    Curr Med Chem; 2019; 26(15):2556-2557. PubMed ID: 31453777
    [No Abstract]   [Full Text] [Related]  

  • 18. Exploring alternative Zn-binding groups in the design of HDAC inhibitors: squaric acid, N-hydroxyurea, and oxazoline analogues of SAHA.
    Hanessian S; Vinci V; Auzzas L; Marzi M; Giannini G
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4784-7. PubMed ID: 16870438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea is a carbonic anhydrase inhibitor.
    Scozzafava A; Supuran CT
    Bioorg Med Chem; 2003 May; 11(10):2241-6. PubMed ID: 12713833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Captopril/enalapril inhibit promiscuous esterase activity of carbonic anhydrase at micromolar concentrations: An in vitro study.
    Esmaeili S; Ashrafi-Kooshk MR; Adibi H; Khodarahmi R
    Chem Biol Interact; 2017 Mar; 265():24-35. PubMed ID: 28126276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.